ADMA BIOLOGICS, INC. Retained Earnings
ADMA BIOLOGICS, INC. (ADMA) had Retained Earnings of -$78.50 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-05
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$78.50M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$116.33M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$161.65M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$211.03M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$78.50M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | -$116.33M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | -$161.65M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | -$211.03M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$247.46M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | -$281.68M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | -$308.58M 10-K · filed 2026-02-25 | |
| 2024-09-30 | -$420.48M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | -$456.39M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$488.45M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | -$506.26M 10-K · filed 2025-03-18 | |
| 2023-09-30 | -$488.61M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | -$491.18M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | -$484.81M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | -$478.02M 10-K · filed 2024-02-28 | -$478.02M 10-K · filed 2023-03-23 |
| 2022-09-30 | -$465.78M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | -$450.89M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | -$437.12M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | -$412.11M 10-K · filed 2023-03-23 | |
| 2021-09-30 | -$395.46M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | -$377.75M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | -$358.85M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | -$340.47M 10-K · filed 2022-03-24 | |
| 2020-09-30 | -$321.06M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | -$304.14M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | -$283.96M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | -$264.72M 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$254.16M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | -$242.72M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | -$229.51M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | -$216.44M 10-K · filed 2020-03-13 | |
| 2018-09-30 | -$198.40M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | -$183.26M 10-Q · filed 2018-08-10 | |
| 2018-03-31 | -$168.52M 10-Q · filed 2018-05-14 | |
| 2017-12-31 | -$150.69M 10-K · filed 2019-03-13 | |
| 2017-09-30 | -$137.71M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | -$122.51M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | -$113.47M 10-Q · filed 2017-05-12 | |
| 2016-12-31 | -$106.93M 10-K · filed 2018-03-29 | |
| 2016-09-30 | -$102.38M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | -$98.04M 10-Q · filed 2016-08-12 | |
| 2016-03-31 | -$92.03M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | -$87.42M 10-K · filed 2017-02-24 | |
| 2015-09-30 | -$82.84M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | -$77.73M 10-Q · filed 2015-08-11 | |
| 2015-03-31 | -$73.06M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | -$69.45M 10-K · filed 2016-03-23 | |
| 2014-09-30 | -$65.89M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | -$62.50M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | -$58.54M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | -$52.64M 10-K · filed 2015-03-09 | |
| 2013-09-30 | -$47.94M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | -$45.25M 10-Q · filed 2013-08-12 | |
| 2013-03-31 | -$40.35M 10-Q · filed 2013-05-14 | |
| 2012-12-31 | -$37.11M 10-K · filed 2014-03-28 | |
| 2012-09-30 | -$34.86M 10-Q · filed 2012-11-13 | |
| 2012-06-30 | -$31.61M 10-Q · filed 2012-08-14 | |
| 2012-03-31 | -$30.41M 10-Q · filed 2012-05-15 | |
| 2011-12-31 | -$29.81M 10-K · filed 2013-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |